期刊文献+

二氯化锶联合唑来膦酸对乳腺癌转移性骨肿瘤患者缓解骨痛及生活质量的影响 被引量:10

Effects of radionuclide strontium dichloride combined with zoledronic acid on relieving bone pain and quality of life in patients with metastatic bone cancer with hormone-dependent breast cancer
原文传递
导出
摘要 目的探究二氯化锶联合唑来膦酸对激素依赖型乳腺癌转移性骨肿瘤患者缓解骨痛及生活质量的影响。方法62例激素依赖型乳腺癌转移性骨肿瘤患者,按治疗方案不同分组,各31例。对照组以二氯化锶治疗,观察组在对照组基础上联合唑来膦酸治疗,随访3个月,对比两组病灶疗效、骨痛缓解情况以及生活质量评分(GQOLI-74)。结果观察组病灶治疗总有效率54.84%(17/31)高于对照组32.26%(10/31),但无差异(P>0.05);骨痛缓解率64.52%(20/31)高于对照组38.71%(12/31)(P<0.05);躯体功能、物质生活状态、心理功能、社会功能评分均高于对照组(P<0.05)。结论二氯化锶联合唑来膦酸疗法能有效保护骨质,缓解骨痛症状,改善生活质量。 Objective To investigate the effects of radionuclide strontium dichloride and zoledronic acid on relieving bone pain and quality of life in patients with metastatic bone cancer with hormone-dependent breast cancer.Methods 62 patients with metastatic bone cancer with hormone-dependent breast cancer were randomly divided into control group and observation group according to the different treatment regimen,each group 31 cases. The control group was treated with radionuclide strontium dichloride,the observation group was treated with zoledronic acid on the basis of the control group,the patients were followed up for 3months. The lesion efficacy,bone pain relief and quality of life score( GQOLI-74) were statistically compared between the two groups.Results: The total effective rate of lesion treatment in the observation group was 54.84%( 17/31) and the control group was 32.26%( 10/31)( P〉0.05); The effective remission rate of bone pain in the observation group was 64.52%( 20/31),the control group was 38.71%( 12/31)( P〈0.05); The physical function,physical status,psychological function and social function score of the observation group were higher than the control group( P〈0.05).Conclusion: Radionuclide strontium dichloride combined with zoledronic acid in the treatment of metastatic bone tumor of hormone-dependent breast cancer can effectively protect the bone,relieve the symptoms of bone pain and improve the life quality of patients.
作者 郭佳 黄际远 戴庆靖 温群芳 宋文忠 GUO Jia I-IUANG Ji-yuan DAI Qing-jing WEN Qun-fang SONG Wen-zhong(People's Hospital of Sichuan Province, Chengdu Sichuan, 610072 China)
出处 《中国地方病防治》 北大核心 2017年第3期258-258,260,共2页 Chinese Journal of Control of Endemic Diseases
基金 四川省人民医院青年人才基金(项目编号2016QN02)
关键词 放射性核素二氯化锶 唑来膦酸 激素依赖型乳腺癌转移性骨肿瘤 生活质量 Radionuclide strontium dichloride Zoledronic acid Hormone-dependent breast cancer metastatic bone tumor Quality of life
  • 相关文献

参考文献2

二级参考文献24

  • 1Goldhirsch A, Winer E P, Coates A S, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013 [ J]. Ann Oncol, 2013, 24 (9) : 2206 - 2223. DOI : 10. 1093/annonc/mdt303. 被引量:1
  • 2Mathew J, Asgeirsson K S, Jackson L R, et al. Neoadjuvant endocrine treatment in primary breast cancer: review of litera- ture [J]. Breast, 2009, 18(6) : 339 -544. DOI: 10. 1016/ j. breast. 2009.09. 012. 被引量:1
  • 3Cilia Y H, Ellis M J, Ma C X. Neoadjuvant endocrine thera- py in primary breast cancer: indications and use as a research tool[J]. Br J Cancer, 2010, 103(6) : 759 -764. DOI: 10. 1038/sj. bjc. 6605845. 被引量:1
  • 4Dixon J M, Anderson T J, Miller W R. Neoadjuvant endo- crine therapy of breast cancer: a surgical perspective[ J]. Eur J Cancer, 2002, 38 (17) : 2214 - 2221. DOI: 10. 1016/ S0959 -8049 ( 02 ) 00265-4. 被引量:1
  • 5Howell A, Cuzick J, Baum M, et al. Rseults of the ATAC (Arimidex, Tamoxifen, Alone or in Combination)trial after completion of 5 years' adjuvant treatment for breast cancer [J].Lancet, 2005, 365(9453): 60-62. DOI: 10. 1016/ S0140-6736 (04) 17666-6. 被引量:1
  • 6Makris A, Powles T J, Ashley S E, et al. A reduction in therequirements for mastectomy in a randomized trial of neoadju- vant chemoendocrine therapy in primary breast cancer [ J ]. Ann Oncol, 1998, 9(11) : 1179 - 1184. 被引量:1
  • 7Smith I E, Dowsett M, Ebbs S R, et al. Neoadjuvant Treat- ment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoper- ative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial[J]. J Clin Oncol, 2005, 23 (22) : 5108 - 5116. DOI: 10. 1200/JCO. 2005.04. 005. 被引量:1
  • 8Alba E, Calvo L, Albanell J, et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in lu- minal breast cancer patients: results from the GEICAM/ 2006-03, a multicenter, randomized, phase-II study [ J ]. Ann Oncol, 2012, 23(12) : 3069 -3074. DOI: 10. 1093/ annonc/mds132. 被引量:1
  • 9Luigi C, Buzdar A, Noguchi S, et al. Comparison of Anas- trozole versus Tamoxifen as Preoperative Therapy in Postm- enopausal Women with Hormone Receptor-Positive Breast Cancer: the Pre-Operative "Arimidex" Compared to Tamox- ifen (PROACT) trial[J]. Cancer, 2006, 106(10): 2095 -2103. DOI: 10. 1002/cncr. 21872. 被引量:1
  • 10Semiglazov V F, Semiglazov V V, Dashyan G A, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen re- ceptorpositive breast cancer [ J ]. Cancer, 2007, 110 ( 2 ) : 244 -254. DOI: 10. 1002/cncr. 22789. 被引量:1

共引文献25

同被引文献92

引证文献10

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部